Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Clinical trial NCT03996473 · TERMINATED
Trial details
- NCT number
- NCT03996473
- Sponsor
- Bayer
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-06
- Primary completion
- 2021-04-14
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.